Cuba vs Europe (WHO region): Pneumococcal conjugate second or third-dose vaccines (PCVc)
Cuba
99.0%
in 2025
Europe (WHO region)
83.0%
in 2025
Cuba rank
1st
Europe (WHO region) rank
3rd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Cuba
- Europe (WHO region)
How they compare
Cuba currently reports 99.0% against 83.0% in Europe (WHO region), a difference of 16.0%.
That makes Cuba's figure about 1.2 times Europe (WHO region)'s.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Europe (WHO region) ahead.
Cuba ranks 1st and Europe (WHO region) ranks 3rd of 194 countries.
Europe (WHO region) has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cuba | Europe (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 15.5% | 15.5% | Europe (WHO region) |
| 2010s | 0.0% | 54.4% | 54.4% | Europe (WHO region) |
| 2020s | 16.5% | 81.8% | 65.3% | Europe (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Cuba or Europe (WHO region)?
- Cuba, at 99.0% against 83.0% in Europe (WHO region) as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Cuba and Europe (WHO region)?
- 16.0%, with Cuba ahead.
- How many years of comparable data are there for Cuba and Europe (WHO region)?
- 18 years are reported by both, from 2008 to 2025.
- How do Cuba and Europe (WHO region) rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Cuba ranks 1st and Europe (WHO region) ranks 3rd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.